Chief Scientific Officer

Jane Hughes

Jane brings 25 years of industry experience in drug discovery and development, with particular focus on target validation, translational research, early clinical development, in-licensing and due-dilligence. She joins Verdiva Bio from Aiolos Bio where she was co-founder and CSO before its acquisition by GSK in 2024. Prior to that, Jane served as VP Translational Research and then CSO at Gyroscope Therapeutics which was acquired by Novartis in 2021.

Jane’s other experience includes GSK where she was Director of Discovery Medicine and translational lead for Otilimab (GSK3196165), as well as time at MedImmune leading the CNS Cell Biology group, driving projects from pre-clinical target validation into clinical development. She also held senior roles at Charles River Laboratories.

Jane began her career at GSK, having received her PhD in Developmental Immunology from Keele University.